New Oral Anticoagulants and Their Reversal

Author(s): Ian Pinto, Anshu Giri, Umbreen Arshad, Ajeet Gajra.

Journal Name: Current Drug Safety

Volume 10 , Issue 3 , 2015

Submit Manuscript
Submit Proposal


The advent of new oral anticoagulants (NOAC) has increased the armamentarium against thromboembolic diseases but has given rise to a conundrum on their reversal. NOAC’s have comparable efficacy to traditional vitamin K antagonists with similar rates of major bleeding. However there is no standardized method for reversal of these agents and no specific antidote. This is of concern not only in acute bleeding episodes but also in clinical scenarios where emergency surgery is required. Recent studies have investigated reversal of dabigatran, rivaroxaban, and apixaban using prothrombin complex concentrates (PCC), recombinant factor VIIa, and in the case of dabigatran, a monoclonal antibody. These studies have been encouraging in showing improvement of bleeding times and blood loss in most models, especially with the use of PCCs and the dabigatran antibody. Of note the majority of common currently used coagulation assays may not correlate with clinical reversal. The management of overt bleeding with NOACs is difficult due to the lack of clinical trials. Current animal trials, case reports and hemostatic testing on human blood have shown some promise; provide guidance but warrant further investigation.

Keywords: Apixaban, dabigitran, new oral anticoagulants, reversal agents, reversal apixaban, reversal dabigitran, reversal of oral anticoagulants, reversal rivaroxiban, rivaroxiban, target specific oral anticoagulants.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [208 - 216]
Pages: 9
DOI: 10.2174/1574886310666150416123530
Price: $58

Article Metrics

PDF: 76